 |
| Date | Title | | | 01/21/10 | Meridian Bioscience Reports Record First Quarter Sales and Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2010 Guidance| CINCINNATI, Jan 21, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
reported record first quarter net sales of $42.5 million, an increase of 24%, over the same period of the prior fiscal year;
reported record first quarter operating income of $13.8 million, an increase of 13%, over the same period of the prior fiscal year;
reported record first quarter earnings and diluted earnings... |
|  | | 11/12/09 | Meridian Bioscience Reports Record Fiscal 2009 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance| CINCINNATI--(BUSINESS WIRE)--Nov. 12, 2009--
Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
reported record fourth quarter and full-year fiscal 2009 net sales of
$42.5 million and $148.3 million, respectively, increases of 16% and
6%, respectively, over the same periods of the prior fiscal year;
reported recor... |
| | | 09/30/09 | Meridian Bioscience Europe Announces Agreement to Distribute Test For GI Disease| CINCINNATI--(BUSINESS WIRE)--Sep. 30, 2009--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announced
today that Meridian Bioscience Europe srl, Milan, Italy has signed an
agreement with BÜHLMANN Laboratories AG, Schönenbuch, Switzerland for
distribution in Italy of an innovative test for inflammatory conditions
of the intestine, Quantum Blue® Calprotectin. The test which
detects calprotectin, a GI inflammatory marker, is a fundamental to... |
| | | 09/17/09 | Meridian Bioscience Granted Special 510(k) Clearance to Add 2009 H1N1 Influenza A Virus Analytical Sensitivity Claim to the TRU FLU(R) Test Package Insert| CINCINNATI--(BUSINESS WIRE)--Sep. 17, 2009--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today
announced that the company has been granted a Special 510(k) clearance
to update the TRU FLU package insert to include analytical sensitivity
claims with two strains of 2009 H1N1 virus cultured from positive
respiratory specimens. TRU FLU is a rapid test which identifies
influenza A and B in human specimens.
Meridian’s T... |
| | | 09/15/09 | Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2010 and Reaffirms Fiscal 2009 Guidance| CINCINNATI--(BUSINESS WIRE)--Sep. 15, 2009--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today provided the financial
community with guidance regarding the Company’s fiscal 2010 sales and
earnings estimates. Based on the Company’s business planning and
budgeting activities for the fiscal year ending September 30, 2010,
management expects net sales to be in the range of $160 to $165 million
and per share diluted earnings to be between $0.90 a... |
| | | 09/03/09 | Meridian Bioscience to Present at the Robert W. Baird 2009 Health Care Conference| CINCINNATI--(BUSINESS WIRE)--Sep. 3, 2009--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced that the Company has been invited to present at the Robert W.
Baird 2009 Health Care Conference on Wednesday, September 9, 2009 at
1:45 p.m. ET at the Four Seasons Hotel New York. Jack Kraeutler, Chief
Executive Officer, and Bill Motto, Executive Chairman of the Board, are
scheduled to present. A question and answer session will foll... |
| | | 07/16/09 | Meridian Bioscience Appoints James M. Anderson to Board of Directors| CINCINNATI--(BUSINESS WIRE)--Jul. 16, 2009--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced that it has appointed James M. Anderson to its Board of
Directors effective immediately.
Mr. Anderson is President and Chief Executive Officer of Cincinnati
Children’s Hospital Medical Center. His appointment as President and CEO
in 1996 followed 20 years of service to the Cincinnati Children’s board
of ... |
| | | 07/16/09 | Meridian Bioscience Reports Record Sales and Operating Results, Declares Regular Cash Dividend, Reaffirms Fiscal 2009 Guidance, and Comments on Timing of Fiscal 2010 Guidance| CINCINNATI--(BUSINESS WIRE)--Jul. 16, 2009--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
reported record quarterly and nine-month sales of $38.2 million and
$105.8 million, respectively, increases of 16% and 3% over the same
periods of the prior fiscal year;
reported record quarterly and nine-month operating income of $12.5
million and $35.7 million, respectively, increases of 14% and
... |
| | | 07/07/09 | FORTUNE Small Business Again Lists Meridian Bioscience as One of America's Fastest-Growing Small Companies| CINCINNATI--(BUSINESS WIRE)--Jul. 7, 2009--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announced
today that FORTUNE Small Business has ranked Meridian Bioscience, Inc.
number 34 on their ninth annual FSB 100 list of the fastest growing
small public companies in America. The list appears in the July/August
issue of FORTUNE Small Business and is available online at http://money.cnn.com/magazines/fsb/fsb100/2009/.
To compile th... |
| | | 06/10/09 | Meridian Bioscience to Present at the William Blair and Company's 29th Annual Growth Stock Conference| CINCINNATI--(BUSINESS WIRE)--Jun. 10, 2009--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the
Company has been invited to present at the William Blair and Company’s 29th
Annual Growth Stock Conference on Thursday, June 11 at 9:20 a.m. CDT at
the Four Seasons Hotel, Chicago, IL. Jack Kraeutler, Chief Executive
Officer, and Bill Motto, Executive Chairman of the Board, are scheduled
to present. A question and answer session will f... |
| | | 06/04/09 | Meridian Bioscience Wins GHX 2009 Best in Class Award| CINCINNATI--(BUSINESS WIRE)--Jun. 4, 2009--
Meridian Bioscience (NASDAQ: VIVO) today announced that it is a
recipient of a 2009 GHX Best in Class Award for achieving the highest
year-over-year market share growth for distributed products in the
Microbiology Reagents/Supplies product category for the 2008 calendar
year.
Meridian Bioscience was among the 30 leading medical-surgical product
manufacturers recognized by GHX in five market... |
| | | 06/03/09 | Meridian Bioscience Receives FDA Clearance for New Rapid Campylobacter Test| CINCINNATI--(BUSINESS WIRE)--Jun. 3, 2009--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has
received FDA clearance from the U.S. Food and Drug Administration (FDA)
for a new rapid test for Campylobacter, ImmunoCard STAT!®
CAMPY. This new test provides fast and accurate detection of Campylobacter
bacteria, one of the most common causes of diarrheal illness and the
most common bacterial cause of foodborne illness in the United Stat... |
| | | 04/16/09 | Meridian Bioscience Reports Record Second Quarter and Six Months Operating Results, Declares Regular Cash Dividend, and Revises Downward Fiscal 2009 Guidance| CINCINNATI, Apr 16, 2009 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
reported second quarter and six months net sales of $33.3 million and
$67.6 million, respectively, decreases of 8% and 4% compared to the
same periods of the prior fiscal year;
reported second quarter and six months operating income of $11.0
million and $23.2 m... |
| |
|
|
|
| |
